MX2022012311A - Citocinas il-2 enmascaradas y sus productos de escisión. - Google Patents
Citocinas il-2 enmascaradas y sus productos de escisión.Info
- Publication number
- MX2022012311A MX2022012311A MX2022012311A MX2022012311A MX2022012311A MX 2022012311 A MX2022012311 A MX 2022012311A MX 2022012311 A MX2022012311 A MX 2022012311A MX 2022012311 A MX2022012311 A MX 2022012311A MX 2022012311 A MX2022012311 A MX 2022012311A
- Authority
- MX
- Mexico
- Prior art keywords
- cytokine
- functional fragment
- masked
- cytokines
- cleavage products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003824P | 2020-04-01 | 2020-04-01 | |
| US202063118571P | 2020-11-25 | 2020-11-25 | |
| PCT/US2021/025103 WO2021202675A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-2 cytokines and their cleavage products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012311A true MX2022012311A (es) | 2023-01-05 |
Family
ID=77928454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012311A MX2022012311A (es) | 2020-04-01 | 2021-03-31 | Citocinas il-2 enmascaradas y sus productos de escisión. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230151072A1 (https=) |
| EP (1) | EP4126247A4 (https=) |
| JP (1) | JP7735306B2 (https=) |
| KR (1) | KR20220161404A (https=) |
| CN (1) | CN115942976A (https=) |
| AU (1) | AU2021245922A1 (https=) |
| BR (1) | BR112022019689A2 (https=) |
| CA (1) | CA3172649A1 (https=) |
| IL (1) | IL296915A (https=) |
| MX (1) | MX2022012311A (https=) |
| PH (1) | PH12022552627A1 (https=) |
| TW (1) | TW202204388A (https=) |
| WO (1) | WO2021202675A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021254283B2 (en) * | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) * | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| MX2024010488A (es) * | 2022-02-28 | 2024-09-05 | Xilio Dev Inc | Citocinas dirigidas y metodos de uso de estas. |
| WO2023164286A1 (en) * | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Engineered cd122 compositions and methods thereof |
| KR20250039361A (ko) * | 2022-07-15 | 2025-03-20 | 실리오 디벨럽먼트, 인크. | 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법 |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025049948A1 (en) * | 2023-08-30 | 2025-03-06 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP2882775B1 (en) * | 2012-08-09 | 2018-02-14 | Roche Glycart AG | Asgpr antibodies and uses thereof |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CN108218993B (zh) * | 2018-01-05 | 2020-11-17 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的双特异性抗体及其制备和应用 |
| WO2019173832A2 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| US12459980B2 (en) * | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN112867503A (zh) * | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
| CN120463822A (zh) * | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022533254A (ja) | 2019-05-24 | 2022-07-21 | プロヴィヴァ セラピューティクス （ホン コン） リミテッド | Ｉｌ－２組成物およびその使用方法 |
-
2021
- 2021-03-31 JP JP2022560205A patent/JP7735306B2/ja active Active
- 2021-03-31 CN CN202180039119.8A patent/CN115942976A/zh active Pending
- 2021-03-31 TW TW110112016A patent/TW202204388A/zh unknown
- 2021-03-31 BR BR112022019689A patent/BR112022019689A2/pt unknown
- 2021-03-31 KR KR1020227037408A patent/KR20220161404A/ko active Pending
- 2021-03-31 PH PH1/2022/552627A patent/PH12022552627A1/en unknown
- 2021-03-31 EP EP21780178.6A patent/EP4126247A4/en active Pending
- 2021-03-31 MX MX2022012311A patent/MX2022012311A/es unknown
- 2021-03-31 AU AU2021245922A patent/AU2021245922A1/en active Pending
- 2021-03-31 CA CA3172649A patent/CA3172649A1/en active Pending
- 2021-03-31 WO PCT/US2021/025103 patent/WO2021202675A1/en not_active Ceased
- 2021-03-31 IL IL296915A patent/IL296915A/en unknown
- 2021-03-31 US US17/995,163 patent/US20230151072A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021245922A1 (en) | 2022-10-13 |
| JP7735306B2 (ja) | 2025-09-08 |
| EP4126247A1 (en) | 2023-02-08 |
| PH12022552627A1 (en) | 2023-01-04 |
| US20230151072A1 (en) | 2023-05-18 |
| BR112022019689A2 (pt) | 2022-12-20 |
| EP4126247A4 (en) | 2024-04-24 |
| CN115942976A (zh) | 2023-04-07 |
| WO2021202675A1 (en) | 2021-10-07 |
| KR20220161404A (ko) | 2022-12-06 |
| CA3172649A1 (en) | 2021-10-07 |
| TW202204388A (zh) | 2022-02-01 |
| JP2023520517A (ja) | 2023-05-17 |
| IL296915A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552627A1 (en) | Masked il-2 cytokines and their cleavage products | |
| PH12022552632A1 (en) | Masked il-12 cytokines and their cleavage products | |
| PH12022552630A1 (en) | Masked il-15 cytokines and their cleavage products | |
| MX2025014293A (es) | Polipeptidos de citocinas enmascaradas | |
| MX2024010488A (es) | Citocinas dirigidas y metodos de uso de estas. | |
| PH12021500030A1 (en) | Il-2 conjugates and methods of use thereof | |
| DK3804716T3 (da) | Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf | |
| UA90695C2 (en) | Potentiators of glutamate receptors | |
| CR10534A (es) | Inhibidores de prolil hidroxilasa | |
| WO2003097051A3 (en) | Use of compounds that are effective as selective opiate receptor modulators | |
| CY1108453T1 (el) | Διαδικασια για την παρασκευη επλερενονης | |
| ATE539042T1 (de) | Gebranntes, keramisches feuerfestes produkt | |
| PE20150780A1 (es) | Sistema de voladura y metodo para controlarla | |
| MX2025003937A (es) | Formas cristalinas de un agente anti-sars cov-2 | |
| LU92202I9 (https=) | ||
| GB2457182A (en) | Downhole trigger device having extrudable time delay material | |
| WO2005057344A3 (en) | Material conveying system including control | |
| WO2006071250A3 (en) | Soluble fragments of the sars-cov spike glycoprotein | |
| WO2008087329A3 (fr) | Nouveau médicament pour le traitement d'un cancer gastrique | |
| ATE482500T1 (de) | Verfahren zur verstärkung durch räumlich- zeitliche frequenzumsetzung und einrichtung zum ausführen des verfahrens | |
| EP1064965A3 (en) | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | |
| ATE377020T1 (de) | Kristallines gamma-lacton der17beta-hydroxy- | |
| EA202190874A1 (ru) | Маскированные цитокиновые полипептиды | |
| WO2019126780A3 (en) | Thermodynamically novel modular marijuana cigarette support system | |
| DK1893213T3 (da) | Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme |